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Chronic Illness Panel, a group of more than two-million indi-
viduals who agreed to participate in surveys conducted by Harris
Interactive Service Bureau. Patients selected had a self-reported
diagnosis of hypertension and were receiving antihypertensive
medication. Questions assessed patients’ antihypertensive med-
ication class, blood pressure before and after initiation of the
medication, improvement in health status related to treatment,
and patients’ overall satisfaction with medication. RESULTS:
Using a web-based patient survey has several advantages. It pro-
vided a quick turn-around time as pilot testing and revising the
questionnaire were completed within a week, with full ﬁelding
of the survey accomplished in two-weeks. Because of the prior
consent, the study bypassed the sometimes lengthy approval
process by an Investigational Review Board. The direct entry of
the data by patients saved time and avoided errors from data
entry by a secondary person. The overall cost of the study was
lower than traditional mailing survey. A majority of missing data
occurred in questions related to patients’ recall of blood pressure
measurements. Data was mostly complete for questions with
subjective answers such as overall satisfaction. The limitations
of the web-based survey method included generalizability and
accuracy of recalled information. CONCLUSIONS: Using a
web-based survey is recommended for obtaining PRO in a timely
manner and at a low cost. However, the information should be
interpreted with care. The study subjects were from a select
group that may render selection bias. In addition, recalled infor-
mation seems difﬁcult to obtain and if reported, its accuracy may
be uncertain.
CARDIOVASCULAR DISEASE—Myocardial Infarction
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OBJECTIVE: Because of the difﬁculty of early Venous Throm-
boembolism (VTE) diagnosis and the serious consequences of the
disease, prophylaxis is routinely indicated in medical at-risk
patients. This study examines the effect of VTE prophylaxis by
examining rate of secondary diagnosis of VTE in myocardial
infarction patients and its impact on overall costs of in-patient
care in order to optimize drug prophylaxis. METHODS: An
administrative database of 720,982 discharges containing ICD-
9-CM coding and other data from hospitals across the US was
analyzed. Study patients had a principal diagnosis of myocardial
infarction, and were prescribed heparin or enoxaparin. Associa-
tions between age, gender, length of stay (LOS), number of 
secondary diagnoses (NSD), drug, in-hospital deaths, overall
hospital costs, and incidence of VTE were studied using logistic
regression. RESULTS: From 8694 patients who met the inclu-
sion criteria, 35 patients (0.40%; two enoxaparin vs. 33 heparin)
showed a secondary diagnosis of VTE. Overall mean hospital
costs (p < 0.0001; OR = 2.685) were found to be signiﬁcantly
different between patients showing a secondary diagnosis of VTE
($30,617.4) and those who did not ($15,689.0). However, when
signiﬁcant clinical and demographic factors were controlled for
like LOS (p < 0.0001; OR = 1.053), in-hospital deaths (p =
0.0121; OR = 3.099), NSD (p < 0.0001; OR = 1.410), and age
(p = 0.0027; OR = 1.041), overall hospital costs were not found
to be signiﬁcantly different (p = 0.4459; OR = 1.255). In patients
who showed a secondary diagnosis of VTE, heparin prescribed
patients incurred higher mean overall hospital costs than enoxa-
parin patients; p < 0.0001 ($31,799.6 vs. $11,112.1), possibly
due to a longer LOS (11.4 days vs. 5.5 days). CONCLUSIONS:
The most cost-effective strategy in this analysis was VTE pre-
vention and enoxaparin was a cost-effective treatment choice.
Rational and adequate VTE prophylaxis needs to be addressed
along with further research on administrative database coding
and documentation issues in order to more fully explore the
application of these ﬁndings for a clinician.
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OBJECTIVES: Results from the pivotal Clopidogrel for the
Reduction of Events During Observation (CREDO) trial demon-
strated that one year of clopidogrel following a percutaneous
coronary intervention (PCI) signiﬁcantly reduced the absolute
combined risk of death, MI, or stroke by 3%. Utilizing 
Canadian Case Mix Group (CMG) costing, we sought to deter-
mine the incremental cost-effectiveness per event prevented over
one-year and estimate the incremental cost-effectiveness per life
year gained (LYG) for a clopidogrel + ASA strategy vs. ASA alone
before and after PCI. METHODS: Canadian health care
resource utilization costs were obtained from Case Mix Group
costing from the 2003 Health Funding and Costing Branch of
Alberta Health and Wellness Report. Cost-effectiveness was
expressed as the incremental cost per event prevented (ICERep)
or cost per life year gained (ICERlyg). Bootstrap methods were
used to estimate the joint distribution of cost and effectiveness
differences between the two arms and obtain 95% conﬁdence
intervals (CI). The Canadian costs of clopidogrel and aspirin
were C$2.40 per 75mg, and C$0.05 per tablet respectively. Life
expectancy in trial survivors was estimated from discounted
Framingham and Saskatchewan data. RESULTS: Total one-year
average cost per patient in clopidrogrel + ASA and ASA alone
arms were C$21,241 and C$20,786 respectively; a difference 
of C$455 (95% CI = -C$495 to C$1391). The ICERep was
C$15,040 with 59% of bootstrapped ICERs less than C$20,000
(87% less than C$50,000). The ICERlyg using Framingham esti-
mates was C$2980 with over 96% of bootstrapped ICERs less
than C$20,000 (98% less than C$50,000). The ICERlyg using
Saskatchewan estimates was C$2369 with over 97% of boot-
strapped ICERs less than C$20,000 (nearly 99% less than
C$50,000). CONCLUSION: Treatment with clopidogrel for 12-
months following PCI is highly cost-effective in the Canadian
health care system.
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Patients who survive an acute myocardial infarction (MI) are at
increased risk of subsequent major cardiovascular events and
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cardiac (often sudden) death. The use of highly puriﬁed omega-
3 polyunsaturated fatty acids (n-3 PUFAs) in addition to 
standard secondary prevention after MI results in a signiﬁcant
reduction in risk of sudden death. OBJECTIVE: To assess the
cost-effectiveness of adding n-3 PUFAs to the current secondary
prevention treatment after acute MI in ﬁve countries (Australia,
Belgium, Canada, Germany, Poland). METHODS: Based on the
clinical outcomes of GISSI-Prevenzione (MI, stroke, revasculari-
sation rate and mortality), a decision model was built in 
DataProTM. The implications of adding n-3 PUFAs to standard
treatment in patients with a recent history of MI were analysed
from the health care payer’s perspective. The time horizon was
3.5 years (identical to GISSI-Prevenzione). Event costs were
based on literature data. Life expectancy data for survivors of
cardiac disease were obtained from the Saskatchewan database
and country-adjusted. Results are expressed as extra cost (€) per
life year gained (LYG). Country-speciﬁc discounting was applied
to costs and effects. RESULTS: Treatment with n-3 PUFAs
yielded between 0.265 (Poland) and 0.289 (Canada) LYG, at an
additional cost of 823€ (Canada) to 1479€ (Belgium). The incre-
mental cost-effectiveness ratio (ICER) varied between 2850€
(Canada) and 5154€ (Belgium) per LYG. Sensitivity analyses on
effectiveness, cost of complications and discounting proved the
robustness of the results. A second order Monte Carlo simula-
tion based on the 95% CIs obtained from GISSI showed that 
n-3 PUFAs are cost-effective in more than 99% of patients
(threshold 20,000€/LYG). Including costs incurred during LYG
considerably increased total costs, but had no impact on the
ICER-based treatment recommendation. CONCLUSIONS:
Adding highly puriﬁed n-3 PUFAs to standard treatment in the
secondary prevention after MI appears to be cost-effective in the
ﬁve countries studied.
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OBJECTIVES: To investigate the cost trend of anticoagulant
drug usage in hospital inpatients, examine the association among
patients’ DRG groups, average length of therapy, and their drug
costs. METHODS: A sample of four-million hospital discharges
from 251 hospitals treated with an anticoagulant (Angiomax,
Argatroban, Arixtra, Coumadin, Dicumarol, Fragmin, Heparin
sodium, Innohep, Lovenox, Miradon, Orgaran ,Reﬂudan and
Thrombate III) between 1998 and 2004 was retrieved. The
sample was also broken out by the DRG group as unstable
angina non-ST-segment elevation myocardial infarction
(UANSTEMI), ST-segment elevation myocardial infarction
(STEMI), deep vein thrombosis (DVT), abdominal disease, and
other group. The average anticoagulant cost was estimated as a
linear function of lab, image, supply,length of therapy,length of
stay,time etc. Analysis of Variance model was created to examine
if the drug volume is determined by drug cost, DRG group, and
average length of therapy. RESULT: Although each single drug
cost per discharge remained unchanged or even decreases over
time, the average anticoagulant drug cost per discharge increases
with time (p-value <+) and with average length of therapy (p-
value <+). This was because newer, or relatively more expensive
drugs like Argatroban, Orgaran, Arixtra and Angiomax etc.
were introduced during the time frame. Drug volume is function
of average length of therapy (p-value <+) and average drug cost
(p-value <+); however, DRG group was not a signiﬁcant factor.
The results held if examining each drug like Lovenox or Heparin
sodium separately. As newer drugs were introduced, the average
length of hospital stay (p-value <+) decreased. CONCLUSION:
The use of large market share drugs (Heparin, Lovenox, Fragmin
etc) remained stable for hospital inpatient over time. However,
there was tendency to use newer, more expensive drugs to
improve clinical outcomes regardless of increasing anticoagulant
drug costs.
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OBJECTIVE: One of the most serious and frequent conse-
quences of acute myocardial infarction is heart failure, which has
moved into the focus of public health care in the last few years.
The presented modeling determines the epidemiological and
health-economic disease burden of post-acute myocardial infarc-
tion heart failure in Germany. METHODS: Basis for the concept
was a literature review of relevant publications since 1990. The
incidence of post-acute myocardial infarction heart failure was
estimated for two scenarios and, with the help of a Markov
model, the course of the disease and the associated use of
resources over a period of nine years was calculated. Subse-
quently, the annual cost of all prevalent cases was determined.
RESULTS: The calculation of the incidence in Germany varies
between 50,000 (best case scenario) and 90,000 (worst case 
scenario) per year. These patients cause total costs of 1.4–2.5 
billion euro during the selected observation period (the portion
of direct costs is approx. 55 %). The prevalence per year is 
estimated to be 250,000 to 450,000. Per year these patients 
cause a ﬁnancial burden of approximately 0.9–1.6 billion Euros.
The majority is due to hospital treatment (0.3–0.5 billion Euros)
and the loss of productivity due to premature mortality (0.2–
0.4 billion Euros). Apart from the rateable monetary strain, it
has to be assumed that after the manifestation of heart failure
the quality of life for these patients is reduced by about 50%
compared to that of the normal population at a comparable age.
CONCLUSION: In light of the heavy ﬁnancial burden—in par-
ticular due to hospital treatment and loss of productivity—
following the manifestation of heart failure, an early and 
effective therapy of the initial myocardial infarction is essential.
If heart insufﬁciency nevertheless develops following myocardial
infarction, optimum secondary preventive strategies are 
necessary.
CARDIOVASCULAR DISEASE—Other
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People with the metabolic syndrome are at increased risk for 
cardiovascular disease (CVD). Screening of metabolic syndrome
allows early recognition of individuals at risk for developing
CVD. OBJECTIVE: To examine the frequency and risk factors
of metabolic syndrome among the Korean Americans living in
New York City. METHODS: This is a cross-sectional health
examination survey. Using a standardized questionnaire, blood
pressure (BP), body mass index (BMI), waist to hip ratio (WHR)
were recorded; serum total cholesterol (TC), high-density
lipoprotein (HDL), fasting triglycerides (FTG), and fasting
